Bexarotene in Preventing Breast Cancer in Patients at High Risk for Breast Cancer

NCT03323658 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

24

Enrollment

NIH

Sponsor class

Conditions

Breast Atypical Ductal Hyperplasia
Breast Atypical Lobular Hyperplasia
Breast Ductal Carcinoma In Situ
Breast Lobular Carcinoma In Situ
Invasive Breast Carcinoma

Interventions

DRUG: Bexarotene
OTHER: Questionnaire Administration

Sponsor

National Cancer Institute (NCI)